AZ posts solid Q1 results as Alexion merger loomsAstraZeneca’s not-for-profit coronavirus vaccine has bit into margins in Q1, although revenues were ahead of expectations as the Share XAZ posts solid Q1 results as Alexion merger loomshttps://pharmaphorum.com/news/az-posts-solid-q1-results-as-alexion-merger-looms/
CHMP backs Roche’s Enspryng for rare nerve disease NMOSDRoche’s Enspryng has been recommended for approval in the EU for treating neuromyelitis optica spectrum disorder (NMOSD), extending Share XCHMP backs Roche’s Enspryng for rare nerve disease NMOSDhttps://pharmaphorum.com/news/chmp-backs-roches-enspryng-for-rare-nerve-disease-nmosd/
NICE recommends Alexion’s long-acting Ultomiris for PNHNICE has recommended Alexion’s long-acting Ultomiris (ravulizumab) for the rare disease paroxysmal nocturnal haemoglobinuria (PNH) in final draft Share XNICE recommends Alexion’s long-acting Ultomiris for PNHhttps://pharmaphorum.com/news/nice-recommends-alexions-long-acting-ultomiris-for-pnh/
Alexion’s Camilla Harder Hartvig on making the impossible possible in rare diseaseAlexion’s senior vice president of its international business talks to Paul Tunnah about the importance of “people-centred and Share XAlexion’s Camilla Harder Hartvig on making the impossible possible in rare diseasehttps://pharmaphorum.com/views-and-analysis/alexions-camilla-harder-hartvig-on-rare-diseases/
J&J’s Darzalex Faspro is first US therapy for rare blood disorderJohnson & Johnson’s Darzalex Faspro has become the first product approved by the FDA to treat light chain Share XJ&J’s Darzalex Faspro is first US therapy for rare blood disorderhttps://pharmaphorum.com/news/jjs-darzalex-faspro-is-first-us-therapy-for-rare-blood-disorder/
Alexion finally has a buyer – and it’s AstraZeneca with $39bn on the tableAlexion has routinely featured among lists of top biopharma takeover prospects in the last couple of years, and Share XAlexion finally has a buyer – and it’s AstraZeneca with $39bn on the tablehttps://pharmaphorum.com/news/alexion-finally-has-a-buyer-and-its-astrazeneca-with-39bn-on-the-table/
Chasing Janssen, Alexion and Caelum start phase 3 AL amyloidosis trialAlexion and development partner Caelum Biosciences have begun late-stage trials of their light-chain (AL) amyloidosis drug CAEL-101, snapping Share XChasing Janssen, Alexion and Caelum start phase 3 AL amyloidosis trialhttps://pharmaphorum.com/news/chasing-janssen-alexion-and-caelum-start-phase-3-al-amyloidosis-trial/
Roche takes on Alexion as FDA approves satralizumab in NMOSDThe FDA has approved Roche’s satralizumab for the rare autoimmune disorder Neuromyelitis Optica Spectrum Disorder (NMOSD), under the Share XRoche takes on Alexion as FDA approves satralizumab in NMOSDhttps://pharmaphorum.com/news/roche-takes-on-alexion-as-fda-approves-satralizumab-in-nmosd/
Alexion trials rare disease drug Ultomiris in severe COVID-19 casesPharma is pretty much throwing everything it has at COVID-19 and US rare disease firm Alexion has joined Share XAlexion trials rare disease drug Ultomiris in severe COVID-19 caseshttps://pharmaphorum.com/news/alexion-trials-rare-disease-drug-ultomiris-in-severe-covid-19-cases/
